Curis (CRIS)

• Market cap: $13.7M
• 1 day: 1.55%
• 5 days: 9.17%
• 1 month: -55.59%
• 3 months: -60.18%
• 6 months: -75.47%
• Year to date: -69.10%
• 1 year: -91.79%
• 5 years: -91.71%
• 10 years: -99.53%
• Sector: Healthcare
• Industry: Biotechnology

About: Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Employees: 33

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

900% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 1

650% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 2

29% more funds holding

Funds holding: 31 [Q3] → 40 (+9) [Q4]

4.25% more ownership

Funds ownership: 33.62% [Q3] → 37.87% (+4.25%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

9% less capital invested

Capital invested by funds: $10.8M [Q3] → $9.82M (-$1.02M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $16 1,121% upside
• Avg. target: $16 1,121% upside
• High target: $16 1,121% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Edward White 24% 1-year accuracy 36 / 149 met price target

1,121% upside $16

Buy Maintained

31 Mar 2025